All type of patients: 1 trials - Emmerich
| etofibrate vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - Emmerich
| etofibrate vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
